CA2236158A1 - Methode pour traiter les blessures des cellules ganglionnaires de la retine en utilisant un agent proteique neurotrophique obtenu de lignees de cellules gliales - Google Patents
Methode pour traiter les blessures des cellules ganglionnaires de la retine en utilisant un agent proteique neurotrophique obtenu de lignees de cellules glialesInfo
- Publication number
- CA2236158A1 CA2236158A1 CA002236158A CA2236158A CA2236158A1 CA 2236158 A1 CA2236158 A1 CA 2236158A1 CA 002236158 A CA002236158 A CA 002236158A CA 2236158 A CA2236158 A CA 2236158A CA 2236158 A1 CA2236158 A1 CA 2236158A1
- Authority
- CA
- Canada
- Prior art keywords
- gdnf
- neurotrophic factor
- derived neurotrophic
- retinal ganglion
- cell line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 title abstract 3
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 title abstract 3
- 210000003994 retinal ganglion cell Anatomy 0.000 title abstract 2
- 230000005779 cell damage Effects 0.000 title 1
- 208000037887 cell injury Diseases 0.000 title 1
- 101150082979 gdnf gene Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000007850 degeneration Effects 0.000 abstract 2
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010056677 Nerve degeneration Diseases 0.000 abstract 1
- 208000030768 Optic nerve injury Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/564,458 US5641749A (en) | 1995-11-29 | 1995-11-29 | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
US08/564,458 | 1995-11-29 | ||
PCT/US1996/018851 WO1997019695A1 (fr) | 1995-11-29 | 1996-11-22 | Methode pour traiter les blessures des cellules ganglionnaires de la retine en utilisant un agent proteique neurotrophique obtenu de lignees de cellules gliales |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2236158A1 true CA2236158A1 (fr) | 1997-06-05 |
CA2236158C CA2236158C (fr) | 2002-07-16 |
Family
ID=24254557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002236158A Expired - Fee Related CA2236158C (fr) | 1995-11-29 | 1996-11-22 | Methode pour traiter les blessures des cellules ganglionnaires de la retine en utilisant un agent proteique neurotrophique obtenu de lignees de cellules gliales |
Country Status (20)
Country | Link |
---|---|
US (1) | US5641749A (fr) |
EP (1) | EP0866719B1 (fr) |
JP (1) | JP4066201B2 (fr) |
KR (1) | KR19990071541A (fr) |
CN (1) | CN1203531A (fr) |
AT (1) | ATE194081T1 (fr) |
BR (1) | BR9611748A (fr) |
CA (1) | CA2236158C (fr) |
CZ (1) | CZ149998A3 (fr) |
DE (1) | DE69609084T2 (fr) |
DK (1) | DK0866719T3 (fr) |
ES (1) | ES2148826T3 (fr) |
GR (1) | GR3034194T3 (fr) |
HU (1) | HUP0001078A2 (fr) |
IL (1) | IL124600A0 (fr) |
MX (1) | MX9803968A (fr) |
NO (1) | NO982276L (fr) |
PT (1) | PT866719E (fr) |
SK (1) | SK65898A3 (fr) |
WO (1) | WO1997019695A1 (fr) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020064870A1 (en) * | 1993-03-03 | 2002-05-30 | Pascale Briand | Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases |
FR2704556B1 (fr) | 1993-04-30 | 1995-07-13 | Rhone Poulenc Rorer Sa | Virus recombinants et leur utilisation en thérapie génique. |
FR2710846B1 (fr) | 1993-10-04 | 1995-12-22 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques et leur utilisation, notamment dans le traitement des maladies neurogénératives. |
US8431119B2 (en) * | 1993-10-04 | 2013-04-30 | Aventis Pharma S.A. | Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases |
US5731284A (en) * | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
US6184200B1 (en) * | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
US5641750A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5741778A (en) * | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
US7276251B2 (en) * | 1997-04-01 | 2007-10-02 | Lg Life Sciences, Ltd., Inc. | Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid |
KR100236771B1 (ko) * | 1997-04-01 | 2000-02-01 | 성재갑 | 히아루론산을 이용한 약물의 서방성 미세입자 제형 |
US6677135B1 (en) | 1996-05-08 | 2004-01-13 | Biogen, Inc. | Ret ligand (RetL) for stimulating neutral and renal growth |
KR100514277B1 (ko) * | 1996-09-13 | 2005-09-13 | 유겐가이샤 사이센딴이가꾸겡꾸쇼 | 신경 영양 인자의 안과용 조성물, 시신경 기능 장애 치료제 및 시신경 기능 장애 치료 방법 |
IT1291892B1 (it) * | 1997-04-24 | 1999-01-21 | Alessandro Lambiase | Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella |
US20030121064A1 (en) * | 1997-06-11 | 2003-06-26 | Ann Logan | CNS neuroregenerative compositions and methods of use |
US6399058B1 (en) * | 1997-09-17 | 2002-06-04 | Alcon Manufacturing, Ltd. | Methods for treating ocular diseases |
US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
US6337340B1 (en) | 1998-08-14 | 2002-01-08 | Gpi Nil Holdings, Inc. | Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders |
US6333340B1 (en) | 1998-08-14 | 2001-12-25 | Gpi Nil Holdings, Inc. | Small molecule sulfonamides for vision and memory disorders |
US6335348B1 (en) | 1998-08-14 | 2002-01-01 | Gpi Nil Holdings, Inc. | Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders |
US6339101B1 (en) | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
US6384056B1 (en) | 1998-08-14 | 2002-05-07 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters or ketones for vision and memory disorders |
US6399648B1 (en) | 1998-08-14 | 2002-06-04 | Gpi Nil Holdings, Inc. | N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders |
US6376517B1 (en) | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
US7338976B1 (en) | 1998-08-14 | 2008-03-04 | Gpi Nil Holdings, Inc. | Heterocyclic esters or amides for vision and memory disorders |
US7410995B1 (en) | 1998-08-14 | 2008-08-12 | Gpi Nil Holdings Inc. | N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders |
US6218423B1 (en) | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
US7265150B1 (en) | 1998-08-14 | 2007-09-04 | Gpi Nil Holdings Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders |
US6506788B1 (en) | 1998-08-14 | 2003-01-14 | Gpi Nil Holdings, Inc. | N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders |
TWI246421B (en) * | 1998-12-03 | 2006-01-01 | Alcon Mfg Ltd | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases |
US6906077B1 (en) * | 1998-12-03 | 2005-06-14 | Alcon Manufacturing, Ltd. | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases |
IT1305294B1 (it) | 1999-01-29 | 2001-05-04 | Alessandro Lambiase | Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari. |
US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
AU3755900A (en) * | 1999-03-15 | 2000-10-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US7653769B2 (en) * | 2006-12-14 | 2010-01-26 | International Business Machines Corporation | Management of devices connected to infiniband ports |
US6821775B1 (en) * | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
JP2002223748A (ja) * | 2001-01-31 | 2002-08-13 | Norio Sakuragawa | 網膜神経節細胞培養用培地、眼科用組成物及び網膜神経節細胞保護剤 |
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
US20030129164A1 (en) * | 2001-12-03 | 2003-07-10 | Flannery John G. | Expression of glial-derived neurotrophic factor for treatment of diseases of the eye |
US20030158112A1 (en) * | 2002-02-15 | 2003-08-21 | Johns Hopkins University School Of Medicine | Selective induction of apoptosis to treat ocular disease |
WO2004050027A2 (fr) * | 2002-12-02 | 2004-06-17 | Genvec, Inc. | Procedes et materiaux destines a traiter des troubles oculaires |
EP2322205A1 (fr) | 2003-04-18 | 2011-05-18 | Biogen Idec MA Inc. | Conjugués polymères de neublastine |
JP4168275B2 (ja) * | 2003-11-17 | 2008-10-22 | 株式会社島津製作所 | 重量測定装置 |
EP1740218A1 (fr) * | 2004-03-12 | 2007-01-10 | Genvec, Inc. | Materiaux pour le traitement des fuites vasculaires dans l'oeil |
ATE474586T1 (de) * | 2004-08-19 | 2010-08-15 | Biogen Idec Inc | Neublastin-varianten |
KR101241551B1 (ko) * | 2004-08-19 | 2013-03-11 | 바이오겐 아이덱 엠에이 인코포레이티드 | 전환 성장 인자 베타 패밀리 단백질의 리폴딩 |
US20060083734A1 (en) * | 2004-10-18 | 2006-04-20 | Henrich Cheng | Composition and method for repairing nerve damage and enhancing functional recovery of nerve |
US20060188481A1 (en) * | 2005-02-22 | 2006-08-24 | Saitama Medical School | Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder |
ITRM20050447A1 (it) * | 2005-08-19 | 2007-02-20 | Anabasis S R L | Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson. |
PL1959925T3 (pl) * | 2005-12-02 | 2017-05-31 | (Osi) Eyetech, Inc. | Mikrocząstki o kontrolowanym uwalnianiu |
TWI501774B (zh) * | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
ES2450065T3 (es) * | 2006-03-01 | 2014-03-21 | Biogen Idec Ma Inc. | Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF |
NZ580947A (en) | 2007-05-01 | 2012-05-25 | Biogen Idec Inc | Compositions and methods for increasing vascularization |
US20110135648A1 (en) * | 2007-08-08 | 2011-06-09 | Biogen Idec Ma Inc. | Anti-neublastin antibodies and uses thereof |
TWI702955B (zh) | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
EP2968462B1 (fr) | 2013-03-15 | 2020-12-23 | The Jackson Laboratory | Procédés favorisant la cicatrisation des plaies et la croissance des poils |
AU2015231439B2 (en) | 2014-03-17 | 2019-11-14 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
US10874798B2 (en) * | 2014-10-15 | 2020-12-29 | P&X Medical Nv | Therapeutic applications of artificial cerebrospinal fluid and tools provided therefor |
KR20170137730A (ko) | 2015-03-02 | 2017-12-13 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법 |
DK3081263T3 (da) * | 2015-04-17 | 2020-03-16 | P&X Medical Nv | Sammensætninger og redskaber til behandling af glaukom |
GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
US11912750B2 (en) | 2016-11-10 | 2024-02-27 | Keros Therapeutics, Inc. | GDNF fusion polypeptides and methods of use thereof |
US11723865B2 (en) * | 2017-02-08 | 2023-08-15 | New Hope Research Foundation, Inc. | Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord |
US11541005B2 (en) * | 2017-02-08 | 2023-01-03 | New Hope Research Foundation, Inc. | Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3986510A (en) * | 1971-09-09 | 1976-10-19 | Alza Corporation | Bioerodible ocular device |
US3995635A (en) * | 1971-09-09 | 1976-12-07 | Alza Corporation | Ocular insert |
US3981303A (en) * | 1971-09-09 | 1976-09-21 | Alza Corporation | Bioerodible ocular device |
US4188373A (en) * | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4217898A (en) * | 1978-10-23 | 1980-08-19 | Alza Corporation | System with microporous reservoir having surface for diffusional delivery of agent |
US4474452A (en) * | 1981-05-13 | 1984-10-02 | Pitney Bowes Inc. | Safety device for cam yoke used in electrophotocopier reciprocating carriage |
JPS5823043A (ja) * | 1981-08-03 | 1983-02-10 | Fuji Xerox Co Ltd | 複写機の濃度自動制御方法 |
US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4474752A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4474751A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
EP0154316B1 (fr) * | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Lymphokine chimiquement modifiée et son procédé de préparation |
US4863457A (en) * | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5106627A (en) * | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5158881A (en) * | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US4882150A (en) * | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
US4865846A (en) * | 1988-06-03 | 1989-09-12 | Kaufman Herbert E | Drug delivery system |
US5011472A (en) * | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
CA2006596C (fr) * | 1988-12-22 | 2000-09-05 | Rika Ishikawa | G-csf modifie chimiquement |
US5221696A (en) * | 1989-03-29 | 1993-06-22 | Alcon Laboratories, Inc. | Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs |
DE69033584T2 (de) * | 1989-10-16 | 2001-03-08 | Amgen Inc., Thousand Oaks | Stammzellenfaktor |
WO1991010470A1 (fr) * | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Dispositifs et procedes d'apport ameliore de facteurs actifs |
US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
KR100242093B1 (ko) * | 1991-09-20 | 2000-02-01 | 그레고리 아보트 | 신경교 유도 신경 영양성 인자 |
US5470582A (en) * | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
JP3645902B2 (ja) * | 1992-02-14 | 2005-05-11 | リジェネロン ファーマシューティカルズ,インコーポレーテッド | 特定の因子による網膜の損傷および変性の防止 |
US5384333A (en) * | 1992-03-17 | 1995-01-24 | University Of Miami | Biodegradable injectable drug delivery polymer |
WO1995017203A1 (fr) * | 1993-12-22 | 1995-06-29 | The University Of Medicine And Dentistry Of New Jersey | Nouvelles sequences d'acides nucleiques isolees a partir de cellules gliales |
US5422116A (en) * | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
US5733875A (en) * | 1994-11-15 | 1998-03-31 | Amgen Inc. | Methods of using GDNF as a neuroprotective agent |
-
1995
- 1995-11-29 US US08/564,458 patent/US5641749A/en not_active Expired - Lifetime
-
1996
- 1996-11-22 WO PCT/US1996/018851 patent/WO1997019695A1/fr not_active Application Discontinuation
- 1996-11-22 CN CN96198645A patent/CN1203531A/zh active Pending
- 1996-11-22 DK DK96942805T patent/DK0866719T3/da active
- 1996-11-22 CZ CZ981499A patent/CZ149998A3/cs unknown
- 1996-11-22 IL IL12460096A patent/IL124600A0/xx unknown
- 1996-11-22 HU HU0001078A patent/HUP0001078A2/hu unknown
- 1996-11-22 ES ES96942805T patent/ES2148826T3/es not_active Expired - Lifetime
- 1996-11-22 CA CA002236158A patent/CA2236158C/fr not_active Expired - Fee Related
- 1996-11-22 EP EP96942805A patent/EP0866719B1/fr not_active Expired - Lifetime
- 1996-11-22 JP JP52058297A patent/JP4066201B2/ja not_active Expired - Fee Related
- 1996-11-22 SK SK658-98A patent/SK65898A3/sk unknown
- 1996-11-22 PT PT96942805T patent/PT866719E/pt unknown
- 1996-11-22 BR BR9611748A patent/BR9611748A/pt not_active Application Discontinuation
- 1996-11-22 DE DE69609084T patent/DE69609084T2/de not_active Expired - Lifetime
- 1996-11-22 AT AT96942805T patent/ATE194081T1/de active
- 1996-11-22 KR KR1019980703815A patent/KR19990071541A/ko not_active Application Discontinuation
-
1998
- 1998-05-19 MX MX9803968A patent/MX9803968A/es unknown
- 1998-05-19 NO NO982276A patent/NO982276L/no unknown
-
2000
- 2000-08-14 GR GR20000401888T patent/GR3034194T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
IL124600A0 (en) | 1998-12-06 |
EP0866719B1 (fr) | 2000-06-28 |
NO982276D0 (no) | 1998-05-19 |
CZ149998A3 (cs) | 1998-08-12 |
GR3034194T3 (en) | 2000-11-30 |
JP4066201B2 (ja) | 2008-03-26 |
MX9803968A (es) | 1998-09-30 |
CA2236158C (fr) | 2002-07-16 |
DE69609084T2 (de) | 2000-11-16 |
DE69609084D1 (de) | 2000-08-03 |
AU1163197A (en) | 1997-06-19 |
PT866719E (pt) | 2000-11-30 |
DK0866719T3 (da) | 2000-08-28 |
JP2000501393A (ja) | 2000-02-08 |
EP0866719A1 (fr) | 1998-09-30 |
NO982276L (no) | 1998-07-29 |
CN1203531A (zh) | 1998-12-30 |
HUP0001078A2 (hu) | 2000-08-28 |
SK65898A3 (en) | 1999-01-11 |
WO1997019695A1 (fr) | 1997-06-05 |
ES2148826T3 (es) | 2000-10-16 |
KR19990071541A (ko) | 1999-09-27 |
US5641749A (en) | 1997-06-24 |
BR9611748A (pt) | 1999-06-01 |
ATE194081T1 (de) | 2000-07-15 |
AU696772B2 (en) | 1998-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2236158A1 (fr) | Methode pour traiter les blessures des cellules ganglionnaires de la retine en utilisant un agent proteique neurotrophique obtenu de lignees de cellules gliales | |
CA2232789A1 (fr) | Methode de traitement de la maladie d'alzheimer au moyen d'un produit proteinique: le facteur neurotrophique derive de lignees cellulaires gliales (gdnf) | |
CA2217565A1 (fr) | Methode de prevention et de traitement de la surdite de perception et des troubles vestibulaires a l'aide d'une proteine du facteur neurotrophique derive des cellules gliales (gdnf) | |
IL124601A0 (en) | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product | |
CA2298414A1 (fr) | Procedes de prevention et de traitement des pertes d'audition a l'aide d'un produit proteique de neurturine | |
EP1666037A3 (fr) | Compositions pour la stimulation de la croissance des neurites | |
AU1505788A (en) | A method and a composition for treating neurological diseases such as migraine, by influencing the nerve cells | |
CA2248087A1 (fr) | Vision amelioree par therapie photodynamique de l'oeil | |
AU4216693A (en) | Enzyme product and method for improving bread quality | |
HUT54624A (en) | Process for producing cyclic amino-acid derivatives and theyr intermediates | |
WO1994024160A3 (fr) | Erythropoïetines-muteines a activite renforcee | |
AU687906B2 (en) | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension | |
CA2353527A1 (fr) | Utilisation de stimulateurs des facteurs neurotrophiques pour le traitement des affections neurodegeneratives ophtalmiques | |
AU592006B2 (en) | Ophthalmic composition for treating nerve degeneration | |
EP1050309A4 (fr) | Promoteurs de secretion du facteur neurotrophique | |
EP1304119A3 (fr) | Procédé de prévention et de traitement des pertes d'audition à l'aide d'un produit protéique de neurturine | |
WO2000021978A3 (fr) | Laminine 5, 13 et 14 ainsi que leurs applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20151123 |